Camonsertib Drug Asset Due Diligence Report 2026

This Camonsertib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Camonsertib can convert its Small molecule drug profile and ATR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Camonsertib (query alias: camonsertib)
Modality / target	Small molecule drug; ATR; ATR inhibitors
Highest global status	Phase 2
Originator	Repare Therapeutics, Inc.
Active developers	Repare Therapeutics, Inc., University of Pennsylvania

The MCP disease footprint includes Non-Small Cell Lung Cancer, Liver metastases, Metastatic Solid Tumor. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05601440	Phase 2	Recruiting	484	Evaluate whether biomarker selection improves outcomes as assessed by RECIST 1.1 for overall response rate
NCT05605509	Phase 2	Completed	28	Response rate of RP-6306 in patients with selected cancers receiving standard agent
NCT05566574	Phase 1/2	Active, not recruiting	49	Phase I - Safety and Tolerability of RP-3500 in combination with radiation therapy

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase Ib/II Trial of Combination RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia

Phase 1/2; n=5; evaluation: not stated. Reported fields: -; -; -

Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656)

Phase 1; n=67; evaluation: Positive. Reported fields: Adverse Event: Gr3 TRAE anemia = 26.9% ; Adverse Event: Gr3 TRAE anemia = 26.9%

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Phase 1; n=51; evaluation: Positive. Reported fields: ORR = 37.5 % ; ORR = 25.9 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Camonsertib addresses Non-Small Cell Lung Cancer, Liver metastases, Metastatic Solid Tumor. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-11-17	Repare finds fix as biotech agrees to XenoTherapeutics buyout	Phase 1	US$94.8M stated total
2024-02-14	Roche hands cancer compound back to Repare after paying out $179M	Phase 1/2	US$125.0M upfront; US$1,200.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Use of ATR inhibitors in combination with radioligand therapy for the treatment of cancer”. The milestone feed surfaced a patent-application signal described as “Use of ATR inhibitors in combination with Anti-PD(l)1 therapy”. The milestone feed surfaced a patent-application signal described as “Use of ATR inhibitors in combination with antiandrogen agent”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO